Medicina
Departamento
Istanbul University
Estambul, TurquíaPublicaciones en colaboración con investigadores/as de Istanbul University (24)
2024
-
Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?
Arthritis Care and Research, Vol. 76, Núm. 1, pp. 88-97
2022
-
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
JTO Clinical and Research Reports, Vol. 3, Núm. 6
2021
-
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
Journal of Thoracic Oncology, Vol. 16, Núm. 5, pp. 860-867
2020
-
Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 35, Núm. 6, pp. 1002-1009
-
Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis
Frontiers in Pediatrics, Vol. 8
2019
-
Equalization of four cardiovascular risk algorithms after systematic recalibration: Individual-participant meta-analysis of 86 prospective studies
European Heart Journal, Vol. 40, Núm. 7, pp. 621-631
2018
-
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
The Lancet, Vol. 392, Núm. 10142, pp. 123-133
2017
-
Erratum to: Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort (Pediatr Nephrol, 10.1007/s00467-016-3469-3)
Pediatric Nephrology
-
Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort
Pediatric Nephrology, Vol. 32, Núm. 1, pp. 139-150
-
Treatment outcome in early diffuse cutaneous systemic sclerosis: The European Scleroderma Observational Study (ESOS)
Annals of the Rheumatic Diseases, Vol. 76, Núm. 7, pp. 1207-1218
-
Use of Repeated Blood Pressure and Cholesterol Measurements to Improve Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis
American Journal of Epidemiology, Vol. 186, Núm. 8, pp. 899-907
2016
-
Optimizing the management of transthyretin familial amyloid polyneuropathy in Europe: early diagnosis and effective care
Current Opinion in Neurology
-
The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients
Nephrology Dialysis Transplantation, Vol. 31, Núm. 6, pp. 1002-1013
2015
-
Renal replacement therapy in Europe: A summary of the 2012 ERA-EDTA Registry Annual Report
Clinical Kidney Journal, Vol. 8, Núm. 3, pp. 248-261
2014
-
Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the international scleroderma renal crisis survey
Seminars in Arthritis and Rheumatism, Vol. 43, Núm. 5, pp. 666-672
-
Glycated hemoglobin measurement and prediction of cardiovascular disease
JAMA - Journal of the American Medical Association, Vol. 311, Núm. 12, pp. 1225-1233
2013
-
2013 classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative
Annals of the Rheumatic Diseases, Vol. 72, Núm. 11, pp. 1747-1755
-
2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative
Arthritis and Rheumatism, Vol. 65, Núm. 11, pp. 2737-2747
2012
-
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
European Journal of Cancer, Vol. 48, Núm. 3, pp. 324-332
-
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise
Arthritis Care and Research, Vol. 64, Núm. 3, pp. 351-357